# US 2016/0250276 A1 · Lissencephaly therapeutic agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250276 A1
- Document ID: US20160250276A1
- Status: Published application
- Kind: A1
- Application number: 15/074,142
- Filed: 2016-03-18
- Published: 2016-09-01
- Earliest claimed: 2010-11-29
- Assignees: Osaka City University
- Applicants: Osaka City University
- Inventors: Shinji Hirotsune
- Web page: https://patentgrep.com/patent/US20160250276A1

## CPC

- A61K 38/05: Dipeptides
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/545: Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: [IMAGE cpc-sch-A61K-0953.gif] , e.g. cephalosporins, {cefaclor, or cephalexine}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An object of the present invention is to provide a medicament and method for treating lissencephaly patients. The present invention provides a lissencephaly therapeutic or preventive agent comprising a compound represented by the general formula (I): wherein R1 is lower alkyl substituted with lower alkoxy, lower alkyl substituted with a heterocyclic group, a heterocyclic group, or a group represented by the formula (IIa): wherein R4 is lower alkyl, R3 is lower alkylene, and m is an integer of 1 to 6; R2 is lower alkyl optionally substituted with phenyl; and R3 is lower alkyl optionally substituted with halogen, lower alkoxy, or phenyl; condensed polycyclic hydrocarbon; or hydrogen.

## Claims

### Claim 1

A method for treating lissencephaly comprising administering to a lissencephaly patient or a pregnant woman who is carrying a lissencephaly fetus, a compound represented by the general formula (I):
wherein R1 is a linear or branched C1-6 alkyl substituted with C1-6 alkoxy; a linear or branched C1-6 alkyl substituted with a heterocyclic group; a heterocyclic group, or a group represented by the formula (IIa):
wherein R4 is a linear or branched C1-6 alkyl; R5 is C1-4 alkylene, and m is an integer of 1 to 6;
R2 is a linear or branched C1-6 alkyl optionally substituted with phenyl; and
R3 is a linear or branched C1-6 alkyl optionally substituted with halogen, a C1-6 alkoxy, or phenyl; a C3-6 cycloalkyl optionally substituted with halogen, C1-6 alkoxy, or phenyl; a condensed polycyclic hydrocarbon; or hydrogen.

### Claim 2 (depends on 1)

The method according to claim 1, wherein R1 is a group represented by the formula (IIb):
wherein n is an integer of 1 to 6.

### Claim 3 (depends on 1)

The method according to claim 1, wherein R1 is a group represented by the formula (IIa):
wherein, R4 is a linear or branched C1-6 alkyl, R5 is C1-4 alkylene, and m is an integer of 1 to 6.

### Claim 4 (depends on 1)

The method according to claim 1, wherein R1 is pyridyl optionally having C1-3 alkyl.

### Claim 5 (depends on 1)

The method according to claim 1, wherein R1 is a heterocyclic group comprising oxygen heteroatom.

### Claim 6 (depends on 1)

The method according to claim 1, wherein R3 is cyclopropyl.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the compound represented by the general formula (I) is selected from the group consisting of
((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 2-methoxyethyl ester,
((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester,
((1S)-1-((((I S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 8-methoxy-3,6-dioxaoctyl ester,
((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 11-methoxy-3,6,9-trioxaundecanyl ester, and
((1S)-1-((((1S)-1-benzyl-3-(cyclopropylamino)-2,3-dioxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 2-(pyridin-2-yl)ethyl ester.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the compound represented by the general formula (I) is ((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclobutylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the compound represented by the general formula (I) is administered by oral administration.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the compound represented by the general formula (I) is administered by intravascular administration.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the compound represented by the general formula (I) is administered at a dose of 50 to 1,200 mg once every two to five days.
